Your browser is no longer supported. Please, upgrade your browser.
IMNP Immune Pharmaceuticals, Inc. monthly Stock Chart
IMNP [NASD]
Immune Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.60 Insider Own8.26% Shs Outstand10.74M Perf Week6.48%
Market Cap12.35M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.70M Perf Month-47.73%
Income-37.60M PEG- EPS next Q- Inst Own5.00% Short Float8.02% Perf Quarter-58.93%
Sales- P/S- EPS this Y46.90% Inst Trans37.69% Short Ratio1.22 Perf Half Y-59.22%
Book/sh-0.01 P/B- EPS next Y- ROA-163.70% Target Price60.00 Perf Year-79.32%
Cash/sh0.00 P/C- EPS next 5Y- ROE-844.90% 52W Range1.01 - 7.15 Perf YTD-68.41%
Dividend- P/FCF- EPS past 5Y44.60% ROI- 52W High-83.91% Beta2.15
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low13.86% ATR0.16
Employees9 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)40.88 Volatility6.50% 12.46%
OptionableNo Debt/Eq- EPS Q/Q81.20% Profit Margin- Rel Volume0.52 Prev Close1.12
ShortableYes LT Debt/Eq- EarningsSep 13 BMO Payout- Avg Volume638.12K Price1.15
Recom1.00 SMA20-0.42% SMA50-29.76% SMA200-59.40% Volume332,910 Change2.68%
Oct-13-15Reiterated Chardan Capital Markets Buy $5 → $6.50
Oct-08-15Initiated ROTH Capital Buy $6
May-18-15Reiterated Chardan Capital Markets Buy $5 → $6
Mar-09-15Initiated Chardan Capital Markets Buy $5.50
Aug-29-17 04:15PM  Immune Pharmaceuticals Receives NASDAQ Letter Business Wire
Aug-28-17 08:00AM  Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial Highlights Business Wire
Aug-24-17 08:00AM  Today's Research Reports on Trending Tickers: Intra-Cellular Therapies and Immune Pharmaceuticals ACCESSWIRE -34.09%
Aug-14-17 08:00AM  Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer Business Wire
Aug-09-17 09:30AM  CYTOVIA Inc, IMMUNE Pharmas Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent Business Wire
Aug-07-17 09:27AM  CYTOVIA Inc., IMMUNE Pharmas Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML) Business Wire
Aug-04-17 10:16AM  Immune Pharmaceuticals, Inc. Issues Letter to Shareholders Business Wire -20.51%
Jul-19-17 09:32AM  Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company Business Wire -7.44%
Jul-13-17 07:30AM  IMMUNE Pharmaceuticals Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1 Business Wire
Jul-11-17 01:45PM  Cytovia Inc, Immune Pharmaceuticals Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America Business Wire
Jul-05-17 08:30AM  IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal PR Newswire
Jun-29-17 08:30AM  Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America PR Newswire +8.42%
Jun-20-17 09:14AM  Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) PR Newswire +5.77%
Jun-19-17 08:30AM  Immune Receives NASDAQ Compliance Letter PR Newswire +5.26%
Jun-15-17 09:28AM  Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene PR Newswire
May-26-17 08:30AM  Immune Receives Nasdaq Letters PR Newswire
May-04-17 09:00AM  Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million PR Newswire
Apr-24-17 08:41AM  Immune Pharma shares tumble 9% premarket as it unveils restructuring MarketWatch -20.96%
08:30AM  Immune Pharmaceuticals Announces Corporate Restructuring PR Newswire
08:15AM  Immune Receives Nasdaq Letter PR Newswire
Apr-21-17 07:30AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals Accesswire
Apr-20-17 10:25AM  Why Immune Pharmaceuticals Shares Are Skyrocketing 24/7 Wall St. +49.59%
09:07AM  Immune Pharma's stock rockets on heavy volume after license pact MarketWatch
08:00AM  Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America PR Newswire
Apr-12-17 07:30AM  Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split PR Newswire -5.48%
Mar-23-17 06:06AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Mar-13-17 05:11PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
09:55AM  Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement PR Newswire
Feb-28-17 08:30AM  Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid PR Newswire -5.31%
Feb-17-17 09:15AM  Immune Pharmaceuticals Announces the launch of REMAIN , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia PR Newswire
Feb-15-17 04:30PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-06-17 08:15AM  Blog Coverage Pfizer Signs Agreement with Citibank to Repurchase $5 Billion Worth of Shares Accesswire
07:20AM  Purcell Julie & Lefkowitz LLP Is Investigating Immune Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Feb-03-17 05:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -5.76%
Feb-01-17 04:03PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +5.21%
Jan-27-17 07:00AM  Immune Pharmaceuticals Appoints New Chairman of the Board of Directors PR Newswire
Jan-23-17 08:45AM  Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment PR Newswire
Jan-19-17 04:02PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events -6.13%
Jan-17-17 09:10AM  Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI PR Newswire
Jan-09-17 06:11PM  Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule PR Newswire
05:26PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Dec-22-16 04:51PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-20-16 04:09PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-16-16 06:03AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Nov-26-16 01:04PM  IMMUNE PHARMACEUTICALS INC Financials
Nov-22-16 09:00AM  Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016 PR Newswire
06:02AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
Nov-18-16 04:11PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -5.00%
Nov-17-16 09:15AM  Immune Pharmaceuticals Secures Up to $11 Million in New Financing to be Deployed With a Focus on Bertilimumab Clinical Development PR Newswire +5.26%
Nov-08-16 04:03PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Oct-28-16 11:20AM  Here Are Three Big Biotech Movers And Our Take On Whats Next at Insider Monkey -12.69%
Oct-27-16 07:00AM  Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene® In Combination with Low Dose IL-2 PR Newswire +38.00%
Oct-17-16 09:23AM  Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary PR Newswire
Sep-16-16 07:58AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St -10.34%
07:30AM  Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary PR Newswire
Sep-07-16 07:33AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E +14.55%
07:30AM  Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share PR Newswire
Aug-18-16 12:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aug-16-16 07:30AM  Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results PR Newswire
Aug-15-16 05:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-05-16 02:15AM  Immune Pharmaceuticals Inc (IMNP) CEO Daniel Gedeon Teper Bought $356,250 of Stocks +15.15%
Aug-03-16 09:27AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Jul-19-16 05:09PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of -10.36%
09:30AM  IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet PR Newswire
Jul-06-16 05:26PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Jul-01-16 06:05AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-28-16 07:00AM  New Data Suggests Improved Tumor Response For The Combination of AZIXA® and Immune Checkpoint Inhibitors in The Treatment of Cancer PR Newswire +5.31%
Jun-21-16 09:00AM  Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter Marketwired +35.22%
Jun-20-16 05:30PM  New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models PR Newswire
08:06AM  Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 PR Newswire
Jun-14-16 07:30AM  Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States PR Newswire
Jun-13-16 05:31PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Jun-07-16 07:56PM  Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases PR Newswire +9.06%
May-16-16 06:39PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +13.21%
05:57PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:30AM  Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results PR Newswire
May-05-16 09:00AM  Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report Marketwired
Apr-28-16 09:00AM  ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report Marketwired +7.42%
Apr-20-16 08:42AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Apr-19-16 07:30AM  New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age PR Newswire +10.00%
Apr-18-16 10:25PM  IMNP: Phase 2 Clinical Trials of Bertilimumab Ongoing; Subsidiary to Develop Immunooncology Products.
Mar-31-16 04:10PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
Mar-30-16 06:41PM  Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results PR Newswire -6.38%
06:10PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-22-16 08:49AM  Keep Reading at noodls
07:30AM  Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology PR Newswire
Mar-17-16 07:30AM  New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting PR Newswire +10.98%
Feb-29-16 05:18PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -9.89%
07:30AM  Immune Pharmaceuticals and The International Pemphigus & Pemphigoid Foundation (IPPF) Celebrate Rare Disease Day PR Newswire
Feb-25-16 07:30AM  Immune Pharmaceuticals Names Dr. Jeff Paley to its Board of Directors PR Newswire
Feb-24-16 07:30AM  Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues PR Newswire
Feb-10-16 09:39AM  Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors PR Newswire +18.92%
Feb-08-16 04:39PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:30AM  Immune Pharmaceuticals to Present at 18th Annual BIO CEO & Investors Conference PR Newswire
Feb-04-16 04:13PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -10.04%
Feb-03-16 07:30AM  Immune Pharmaceuticals Names John Neczesny to its Board of Directors PR Newswire -8.08%
Jan-15-16 04:46PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Jan-12-16 08:00AM  Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan PR Newswire +6.18%
Jan-11-16 04:31PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or -12.85%
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis. The company's immuno-oncology pipeline includes Ceplene for the maintenance of remission in patients with acute myeloid leukemia, which is in Phase III clinical trial in the United States and has approved in European Union; Crolibulin, a small molecule vascular disrupting agents (VDA) and apoptosis inducer that is in Phase II clinical trial for the treatment of patients with solid tumors; Azixa, a Phase II microtubular destabilizer that functions as a VDA; NanomAbs, a preclinical stage antibody-drug conjugate platform that allows the targeted delivery of combinations of chemotherapeutics into cancer cells; and bispecific antibodies, which are in preclinical stage against immune-oncology targets. In addition, it develops AmiKet, a prescription topical analgesic cream that has completed II clinical trials for the treatment of neuropathic pain; and LidoPAIN, an adhesive-backed, lidocaine-based patch that is in Phase II clinical trial for the treatment of acute lower back pain. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kazado DanielDirectorJan 04Buy0.1976,50314,2221,145,171Jan 04 05:09 PM
Kazado DanielDirectorDec 16Buy0.19161,37730,0001,068,667Dec 20 08:44 PM
Teper Daniel GedeonCEOOct 06Option Exercise0.04185,4737,4195,865,280Oct 11 06:10 PM